share_log

Recursion Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Recursion Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Recursion Pharmaceuticals | 10-Q:2024财年三季报
美股SEC公告 ·  11/06 16:23

Moomoo AI 已提取核心信息

Recursion Pharmaceuticals, a clinical-stage TechBio company, reported a net loss of $95.8 million for the third quarter of 2024, a slight increase from the $93.0 million loss in the same period of 2023. The nine-month period ended September 30, 2024, saw a net loss of $284.8 million, compared to $235.1 million in 2023. Despite the losses, operating revenue showed significant growth, with a more than 100% increase to $26.1 million for the quarter and a 62% rise to $54.3 million for the nine-month period. This growth was attributed to the strategic partnership with Roche, including a $30.0 million acceptance fee for a neuroscience Phenomap. Recursion's operating costs and expenses also rose, with research and development expenses climbing to $74.6 million for the quarter, up 7% from the previous year. General and administrative...Show More
Recursion Pharmaceuticals, a clinical-stage TechBio company, reported a net loss of $95.8 million for the third quarter of 2024, a slight increase from the $93.0 million loss in the same period of 2023. The nine-month period ended September 30, 2024, saw a net loss of $284.8 million, compared to $235.1 million in 2023. Despite the losses, operating revenue showed significant growth, with a more than 100% increase to $26.1 million for the quarter and a 62% rise to $54.3 million for the nine-month period. This growth was attributed to the strategic partnership with Roche, including a $30.0 million acceptance fee for a neuroscience Phenomap. Recursion's operating costs and expenses also rose, with research and development expenses climbing to $74.6 million for the quarter, up 7% from the previous year. General and administrative expenses increased by 29% to $37.8 million. The company's cash and cash equivalents stood at $427.6 million as of September 30, 2024, which they believe will fund operations for at least the next twelve months. Recursion continues to focus on its pipeline, including clinical trials for various treatments such as Cerebral Cavernous Malformation and Neurofibromatosis Type 2, and expects to share more data in the coming years. The company also highlighted its expanded collaboration with Google Cloud to support its drug discovery platform and the potential acquisition of Exscientia, which is subject to certain closing conditions.
临床阶段的TechBio公司Recursion Pharmaceuticals报告了2024年第三季度亏损9580万美元,与2023年同期亏损9300万美元相比略有增加。截至2024年9月30日的九个月期间,净亏损为28480万美元,而2023年为23510万美元。尽管亏损,营业收入却显著增长,季度增长超过100%,达到2610万美元,九个月期间增长62%,达到5430万美元。这种增长归因于与罗氏的战略合作伙伴关系,其中包括针对神经系统Phenomap的3000万美元接受费用。Recursion的营业成本和费用也上升,研发费用季度上升至7460万美元,比去年同期增长了7%。总务及行政费用增长了...展开全部
临床阶段的TechBio公司Recursion Pharmaceuticals报告了2024年第三季度亏损9580万美元,与2023年同期亏损9300万美元相比略有增加。截至2024年9月30日的九个月期间,净亏损为28480万美元,而2023年为23510万美元。尽管亏损,营业收入却显著增长,季度增长超过100%,达到2610万美元,九个月期间增长62%,达到5430万美元。这种增长归因于与罗氏的战略合作伙伴关系,其中包括针对神经系统Phenomap的3000万美元接受费用。Recursion的营业成本和费用也上升,研发费用季度上升至7460万美元,比去年同期增长了7%。总务及行政费用增长了29%,达到3780万美元。截至2024年9月30日,该公司的现金及现金等价物为42760万美元,他们认为可以支持至少未来12个月的运营。Recursion继续专注于其产品线,包括针对多种治疗方案的临床试验,如大脑海绵状血管瘤和神经纤维瘤2型,并计划在未来几年分享更多数据。该公司还强调了与谷歌云的扩大合作,以支持其药物发现平台,以及潜在收购Exscientia,此收购取决于特定的关闭条件。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息